Holen Sie sich die Stockscreener-App
81.54
0.59%
-0.48
Schlusskurs vom Vortag:
$82.02
Offen:
$81.76
24-Stunden-Volumen:
187.28K
Relative Volume:
0.69
Marktkapitalisierung:
$965.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.80%
1M Leistung:
-21.25%
6M Leistung:
+82.66%
1J Leistung:
+307.70%
1-Tages-Spanne:
$81.46
$85.70
1-Wochen-Bereich:
$76.50
$85.70
52-Wochen-Spanne:
$17.31
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
81.54 | 970.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Mizuho | Outperform |
| 2025-12-05 | Eingeleitet | BTIG Research | Buy |
| 2025-12-04 | Eingeleitet | Craig Hallum | Buy |
| 2025-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
Is Palvella Therapeutics Inc. stock trending bullishWeekly Stock Analysis & Risk Controlled Stock Alerts - mfd.ru
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Published on: 2026-02-13 13:12:26 - mfd.ru
Topical statins show promise for rare skin disease in new review - MSN
Published on: 2026-02-12 04:26:17 - mfd.ru
FY2030 Earnings Forecast for PVLA Issued By HC Wainwright - Defense World
FY2030 Earnings Estimate for PVLA Issued By HC Wainwright - MarketBeat
Topical Statins Show Promise for Rare Skin Disease in New Review - MyChesCo
Notable Friday Option Activity: PVLA, XOM, RUM - Nasdaq
Palvella Therapeutics stock maintains Buy rating at Clear Street ahead of trial data - Investing.com Canada
Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright - The Globe and Mail
LGND: New Year Program Updates - Zacks Small Cap Research
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), HOYA (HOCPF) - The Globe and Mail
Palvella Therapeutics, Inc. Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Por - marketscreener.com
Palvella stock rises after systematic review supports clinical potential By Investing.com - Investing.com Nigeria
Palvella stock rises after systematic review supports clinical potential - Investing.com
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porok... - Sahm
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Poroker - ChartMill
TD Cowen raises Palvella Therapeutics stock price target on BTD prospects - Investing.com Canada
Death Cross: Is CYCU in a bullish channelLayoff News & Technical Confirmation Trade Alerts - baoquankhu1.vn
Federated Hermes Inc. Takes $21.26 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc Advances Late-Stage Pipeline - TradingView
Palvella Therapeutics' (PVLA) Buy Rating Reaffirmed at BTIG Research - MarketBeat
What are the risks of holding Dakota Gold Corp. Equity WarrantJuly 2025 Trends & Verified Short-Term Trading Plans - baoquankhu1.vn
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.8%Here's Why - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Pursues Targeted Immune Innovation - Kalkine Media
Published on: 2026-01-23 00:45:18 - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
FOMO Trade: Does RAIN stock benefit from AI growthQuarterly Profit Report & Short-Term High Return Ideas - baoquankhu1.vn
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from BTIG Research - MarketBeat
Palvella taps veteran dermatology executive to steer medical affairs push - MSN
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Palvella’s rare-disease pipeline gains momentum amid positive topline data - S&P Global
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):